Scientists at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed pyridazinopyridone derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors. As such, they are reported to be useful for the treatment of cancer, gingival fibromatosis, cardiofaciocutaneous and Noonan syndromes.